GH Research PLC Announces Pricing of Initial Public Offering

166
26
Favorite

GH Research PLC Announces Pricing of Initial Public Offering

StreetInsider2021-06-25

DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

166

Report

Comment（26）

Liha
·2021-06-25
Need T
Reply
Like
Report
Crystall
·2021-06-25
Like and comment [Smile]
Reply
3
Report
Fold Replies
- Watercloset:
  Ok
  2021-08-04
  Reply
  Report
- Juneriq:
  please like me
  2021-06-25
  Reply
  Report
- Juneriq:
  please like back
  2021-06-25
  Reply
  Report
View more 1 comments
honkfish
·2021-06-25
Cute n nice
Reply
Like
Report
Lovethatch
·2021-06-25
??
Reply
Like
Report
fuddlewuddle
·2021-06-25
Cool
Reply
Like
Report
Fold Replies
- wenhao88:
  yeah
  2021-06-25
  Reply
  Report
BenjaminTan
·2021-06-25
Nice news
Reply
Like
Report
szueyann
·2021-06-25
Please like and comment. Thanks
Reply
1
Report
Fold Replies
- ponyinvestor:
  Give Me a like pls
  2021-06-25
  Reply
  Report
- szueyann:
  thanks
  2021-06-25
  Reply
  Report
Mourinho10
·2021-06-25
Good
Reply
Like
Report
Bossman
·2021-06-25
Nice
Reply
1
Report
Fold Replies
- weijie123:
  help like and comment
  2021-06-25
  Reply
  Report
Asim
·2021-06-25
Commenting
Reply
Like
Report
yteaaron88
·2021-06-25
Nice
Reply
Like
Report
Vin309
·2021-06-25
Great
Reply
1
Report
RexChuah
·2021-06-25
Comment and like please
Reply
1
Report
Fold Replies
- cxseah:
  Comment
  2021-06-25
  Reply
  Report
cxseah
·2021-06-25
Interesting
Reply
Like
Report
Fold Replies
- huathuatss:
  yeah
  2021-06-25
  Reply
  Report
Jasi
·2021-06-25
Good
Reply
2
Report
kimchee
·2021-06-25
Nice
Reply
1
Report
Daydream22
·2021-06-25
Thanks
Reply
4
Report
maiku
·2021-06-25
Oh
Reply
1
Report
etan000
·2021-06-25
Ok
Reply
3
Report
leoworm
·2021-06-25
Good
Reply
2
Report
Fold Replies
- 50160107Acct:
  G
  2021-06-25
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2146293990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-25 09:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2146293990","market":"us","top_or_hot":-1,"title":"GH Research PLC Announces Pricing of Initial Public Offering","media":"StreetInsider","content":"<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GHRS","symbol_name":"GH Research PLC","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","article_id":"2146293990","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","pubTimestamp":1624583160,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GHRS":"GH Research PLC"},"translate_title":"GH Research PLC公布首次公开发行定价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GHRS":0.9},"content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":122353730,"gmtCreate":1624599234320,"gmtModify":1703841425865,"author":{"id":"3580021038510346","authorId":"3580021038510346","name":"Liha","avatar":"https://static.tigerbbs.com/a4ba484754a4e8fc7a7c54ab52161218","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3580021038510346","idStr":"3580021038510346"},"htmlText":"Need T","listText":"Need T","text":"Need T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122353730","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":122919797,"gmtCreate":1624592262619,"gmtModify":1703841228277,"author":{"id":"3583297255879530","authorId":"3583297255879530","name":"Crystall","avatar":"https://static.tigerbbs.com/54fd10043f5da3238cff16e5780abdd2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3583297255879530","idStr":"3583297255879530"},"htmlText":"Like and comment [Smile]&nbsp;","listText":"Like and comment [Smile]&nbsp;","text":"Like and comment [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/122919797","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5422953,"gmtCreate":1628063461527,"gmtModify":1663231913740,"authorId":3584092741735483,"author":{"id":3584092741735483,"idStr":"3584092741735483","authorId":3584092741735483,"name":"Watercloset","avatar":"https://static.tigerbbs.com/1d1d0d3c3e687a60e8491fa5601ea354","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":122919797,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5008965,"gmtCreate":1624596783189,"gmtModify":1663229981247,"authorId":3566969992567848,"author":{"id":3566969992567848,"idStr":"3566969992567848","authorId":3566969992567848,"name":"Juneriq","avatar":"https://static.tigerbbs.com/2ddc6553edddfa241ccd2e6cf2419f1f","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":122919797,"type":1,"supId":5008961,"prevId":0,"content":"please like <u>me</u>","text":"please like <u>me</u>","html":"please like <u>me</u>"},{"id":5008961,"gmtCreate":1624596766546,"gmtModify":1663229979251,"authorId":3566969992567848,"author":{"id":3566969992567848,"idStr":"3566969992567848","authorId":3566969992567848,"name":"Juneriq","avatar":"https://static.tigerbbs.com/2ddc6553edddfa241ccd2e6cf2419f1f","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":122919797,"type":1,"supId":0,"prevId":0,"content":"please like <u>back</u>","text":"please like <u>back</u>","html":"please like <u>back</u>"},{"id":5007938,"gmtCreate":1624592419574,"gmtModify":1635247220222,"authorId":3584092741735483,"author":{"id":3584092741735483,"idStr":"3584092741735483","authorId":3584092741735483,"name":"Watercloset","avatar":"https://static.tigerbbs.com/1d1d0d3c3e687a60e8491fa5601ea354","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":122919797,"type":1,"supId":0,"prevId":0,"content":"[Smile]","text":"[Smile]","html":"[Smile]"}],"langContent":"EN"},{"id":122080056,"gmtCreate":1624587978075,"gmtModify":1703841097403,"author":{"id":"3574848576018567","authorId":"3574848576018567","name":"honkfish","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3574848576018567","idStr":"3574848576018567"},"htmlText":"Cute n nice","listText":"Cute n nice","text":"Cute n nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122080056","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":122015653,"gmtCreate":1624587893472,"gmtModify":1703841093669,"author":{"id":"3576922039448359","authorId":"3576922039448359","name":"Lovethatch","avatar":"https://static.tigerbbs.com/a0fb3d1e880db90e142ed924bea5128b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3576922039448359","idStr":"3576922039448359"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122015653","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":122091098,"gmtCreate":1624586985814,"gmtModify":1703841057363,"author":{"id":"3586167249120391","authorId":"3586167249120391","name":"fuddlewuddle","avatar":"https://static.tigerbbs.com/8c8ac14ee4c82db6e2556d05e2dadebf","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586167249120391","idStr":"3586167249120391"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/122091098","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5006713,"gmtCreate":1624587418866,"gmtModify":1663229966545,"authorId":3584079580175921,"author":{"id":3584079580175921,"idStr":"3584079580175921","authorId":3584079580175921,"name":"wenhao88","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":122091098,"type":1,"supId":0,"prevId":0,"content":"yeah","text":"yeah","html":"yeah"}],"langContent":"EN"},{"id":126775264,"gmtCreate":1624586488658,"gmtModify":1703841034480,"author":{"id":"3554889732454934","authorId":"3554889732454934","name":"BenjaminTan","avatar":"https://static.tigerbbs.com/4afb434adae9c250eaa4292bab0f9878","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3554889732454934","idStr":"3554889732454934"},"htmlText":"Nice news","listText":"Nice news","text":"Nice news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126775264","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126741934,"gmtCreate":1624586016628,"gmtModify":1703841013287,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"htmlText":"Please like and comment. Thanks","listText":"Please like and comment. Thanks","text":"Please like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/126741934","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5006314,"gmtCreate":1624586229135,"gmtModify":1663229967936,"authorId":3575443999456708,"author":{"id":3575443999456708,"idStr":"3575443999456708","authorId":3575443999456708,"name":"ponyinvestor","avatar":"https://static.tigerbbs.com/138d1ebc8820019726a687f0ffe45994","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126741934,"type":1,"supId":0,"prevId":0,"content":"Give Me a like pls","text":"Give Me a like pls","html":"Give Me a like pls"},{"id":5016835,"gmtCreate":1624634713388,"gmtModify":1635246501775,"authorId":3573721781255613,"author":{"id":3573721781255613,"idStr":"3573721781255613","authorId":3573721781255613,"name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126741934,"type":1,"supId":5006314,"prevId":0,"content":"thanks","text":"thanks","html":"thanks"}],"langContent":"EN"},{"id":126722488,"gmtCreate":1624585496644,"gmtModify":1703840991872,"author":{"id":"3552204947633728","authorId":"3552204947633728","name":"Mourinho10","avatar":"https://static.tigerbbs.com/09c0bff118437529aa16b4350b6facdb","vip":1,"crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3552204947633728","idStr":"3552204947633728"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126722488","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126767593,"gmtCreate":1624585293312,"gmtModify":1703840982746,"author":{"id":"3575284954426905","authorId":"3575284954426905","name":"Bossman","avatar":"https://static.tigerbbs.com/8a9a688341be7e4586cefc976cf56647","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575284954426905","idStr":"3575284954426905"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/126767593","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5006047,"gmtCreate":1624585633162,"gmtModify":1663229965230,"authorId":3575205207637336,"author":{"id":3575205207637336,"idStr":"3575205207637336","authorId":3575205207637336,"name":"weijie123","avatar":"https://static.tigerbbs.com/f79451a0e5ae21cfbd9c59c760eed0a7","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.98%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126767593,"type":1,"supId":0,"prevId":0,"content":"help like and comment","text":"help like and comment","html":"help like and comment"}],"langContent":"EN"},{"id":126764283,"gmtCreate":1624585267342,"gmtModify":1703840980639,"author":{"id":"3580880974870902","authorId":"3580880974870902","name":"Asim","avatar":"https://static.tigerbbs.com/ac8d8b0f6d3fdcd1b0e9c68c7c4b73ed","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3580880974870902","idStr":"3580880974870902"},"htmlText":"Commenting&nbsp;","listText":"Commenting&nbsp;","text":"Commenting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126764283","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126762692,"gmtCreate":1624585176916,"gmtModify":1703840980962,"author":{"id":"3586955264029856","authorId":"3586955264029856","name":"yteaaron88","avatar":"https://static.tigerbbs.com/b5a9adeb4d55b3f87731ddb20a7b5fba","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3586955264029856","idStr":"3586955264029856"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126762692","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126762327,"gmtCreate":1624585165469,"gmtModify":1703840977245,"author":{"id":"3555908735229300","authorId":"3555908735229300","name":"Vin309","avatar":"https://static.tigerbbs.com/9ca4de1ca05f1d625f1bcdbc1d790726","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3555908735229300","idStr":"3555908735229300"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126762327","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126766037,"gmtCreate":1624585122529,"gmtModify":1703840975300,"author":{"id":"3581973369158219","authorId":"3581973369158219","name":"RexChuah","avatar":"https://static.tigerbbs.com/a23f878e37c5d6c2d9ea1558710f63f3","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3581973369158219","idStr":"3581973369158219"},"htmlText":"Comment and like please&nbsp;","listText":"Comment and like please&nbsp;","text":"Comment and like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/126766037","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5005899,"gmtCreate":1624585148751,"gmtModify":1663229964233,"authorId":3586519067840195,"author":{"id":3586519067840195,"idStr":"3586519067840195","authorId":3586519067840195,"name":"cxseah","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126766037,"type":1,"supId":0,"prevId":0,"content":"Comment","text":"Comment","html":"Comment"}],"langContent":"EN"},{"id":126768452,"gmtCreate":1624585113476,"gmtModify":1703840974653,"author":{"id":"3586519067840195","authorId":"3586519067840195","name":"cxseah","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3586519067840195","idStr":"3586519067840195"},"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/126768452","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5005974,"gmtCreate":1624585420474,"gmtModify":1663229965149,"authorId":3579224382437305,"author":{"id":3579224382437305,"idStr":"3579224382437305","authorId":3579224382437305,"name":"huathuatss","avatar":"https://static.tigerbbs.com/45bd8c44245b78706492a732ed831e17","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126768452,"type":1,"supId":0,"prevId":0,"content":"<u>yeah</u>","text":"<u>yeah</u>","html":"<u>yeah</u>"}],"langContent":"EN"},{"id":126786439,"gmtCreate":1624584754721,"gmtModify":1703840962607,"author":{"id":"3585633154315529","authorId":"3585633154315529","name":"Jasi","avatar":"https://static.tigerbbs.com/3797b4a9d790568c56f963430dcac484","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3585633154315529","idStr":"3585633154315529"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126786439","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126786011,"gmtCreate":1624584743533,"gmtModify":1703840961639,"author":{"id":"3577698241216495","authorId":"3577698241216495","name":"kimchee","avatar":"https://static.tigerbbs.com/20d57f31617135242b3762416384face","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3577698241216495","idStr":"3577698241216495"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126786011","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126789320,"gmtCreate":1624584676760,"gmtModify":1703840955655,"author":{"id":"3581848250199772","authorId":"3581848250199772","name":"Daydream22","avatar":"https://static.tigerbbs.com/2ca618e8fa64e89b0f0743ed37962161","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3581848250199772","idStr":"3581848250199772"},"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126789320","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126715719,"gmtCreate":1624584546931,"gmtModify":1703840950166,"author":{"id":"4087266473385580","authorId":"4087266473385580","name":"maiku","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4087266473385580","idStr":"4087266473385580"},"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126715719","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126713966,"gmtCreate":1624584362755,"gmtModify":1703840941808,"author":{"id":"3582010497192751","authorId":"3582010497192751","name":"etan000","avatar":"https://static.tigerbbs.com/3cf965ffd3853f655731971c5c39433f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3582010497192751","idStr":"3582010497192751"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126713966","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126734923,"gmtCreate":1624584226762,"gmtModify":1703840936143,"author":{"id":"3554294506154172","authorId":"3554294506154172","name":"leoworm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3554294506154172","idStr":"3554294506154172"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/126734923","repostId":2146293990,"repostType":4,"repost":{"id":"2146293990","pubTimestamp":1624583160,"share":"https://ttm.financial/m/news/2146293990?lang=&edition=fundamental","pubTime":"2021-06-25 09:06","market":"us","language":"en","title":"GH Research PLC Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2146293990","media":"StreetInsider","summary":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company de","content":"<p>DUBLIN, June 24, 2021 /PRNewswire/ -- <a href=\"https://laohu8.com/S/GHRS\">GH Research PLC</a>, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research <a href=\"https://laohu8.com/S/PLC\">PLC</a>. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.</p>\n<p><img src=\"https://static.tigerbbs.com/a94eadf8f71ac3070a72d96fa1977551\" tg-width=\"400\" tg-height=\"69\" referrerpolicy=\"no-referrer\"></p>\n<p>Cowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</p>\n<p>In any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").</p>\n<p>This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.</p>\n<p>Contact:investors@ghres.com</p>\n<p><b>About GH Research PLC </b></p>\n<p>GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research PLC Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research PLC Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18603637><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18603637\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GHRS":"GH Research PLC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18603637","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146293990","content_text":"DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an initial public offering price of $16 per share for total gross proceeds of approximately $160 million. All of the ordinary shares are being offered by GH Research PLC. The ordinary shares are expected to begin trading on the Nasdaq Global Market on June 25, 2021 under the ticker symbol \"GHRS.\" The offering is expected to close on June 29, 2021, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 ordinary shares at the initial public offering price, less underwriting discounts and commissions.\n\nCowen and Stifel are acting as joint book-running managers for the offering. Canaccord Genuity and JMP Securities are acting as lead managers for the offering.\nA registration statement relating to these securities became effective on June 24, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com. For the avoidance of doubt, such prospectus will not constitute a \"prospectus\" for the purposes of Regulation (EU) 2017/1129 (the \"Prospectus Regulation\") and will not have been reviewed by any competent authority in any European Union member state or the United Kingdom.\nA registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the \"SEC\"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nIn any member state of the European Economic Area (the \"EEA\") this announcement and any offering are only addressed to and directed at persons who are \"qualified investors\" (\"Qualified Investors\") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \"Order\"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as \"Relevant Persons\").\nThis announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not Relevant Persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, Relevant Persons, and (ii) in any member state of the EEA, Qualified Investors.\nContact:investors@ghres.com\nAbout GH Research PLC \nGH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5005799,"gmtCreate":1624584729868,"gmtModify":1663229963046,"authorId":3582706615498692,"author":{"id":3582706615498692,"idStr":"3582706615498692","authorId":3582706615498692,"name":"50160107Acct","avatar":"https://static.tigerbbs.com/6be9d18c4a63434e372aa39f7de3ec12","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126734923,"type":1,"supId":0,"prevId":0,"content":"G","text":"G","html":"G"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":166,"commentSize":26,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}